Cryo-Cell International, Inc. (CCEL)

Over the past six months, Cryo-Cell International, Inc.'s stock price has declined by approximately 33.67%, with a 52-week range between $2.72 and $6.65. Key financial reporting events include the fiscal third-quarter 2025 results reported on October 15, 2025, the fiscal year ended November 30, 2025 results reported on February 27, 2026, a dividend update on August 14, 2025, and a NYSE American continued listing notice in March 2026.

Based on the available information, there is no explicit mention of significant demand seasonality for Cryo-Cell International, Inc.'s products and services. The company operates on a subscription-based business model, which typically provides a steady stream of recurring revenue, suggesting that demand may be relatively stable throughout the year.

Cryo-Cell International, Inc. (CCEL) is a biotechnology company specializing in cellular processing and cryogenic storage services within the Healthcare sector. Founded in 1989, it was the first private cord blood bank to separate and store stem cells. Its services include umbilical cord blood and tissue stem cell preservation, public cord blood banking, the PrepaCyte CB Processing System, cold storage services, adipose tissue banking, and a patented method for endometrial stem cells.

Cryo-Cell International, Inc. is headquartered in Oldsmar, Florida, United States. The company serves a broad international market, with its services available in the United States and 13 other countries: Chile, Costa Rica, Ecuador, El Salvador, Guatemala, Honduras, India, Mexico, Nicaragua, Pakistan, Panama, Peru, the Dominican Republic, and Venezuela.

Cryo-Cell International maintains a strong brand reputation as the world's first private cord blood bank and an internationally recognized industry leader, trusted by over 500,000 parents from 87 countries. The company emphasizes its cutting-edge processing technologies and adherence to high-quality standards, including FDA registration, cGMP-/cGTP-compliance, and accreditations from the American Association of Blood Banks (AABB) and FACT. The company has continued to highlight its long-standing public bank partnership with Duke University and anticipates opening infusion clinics to treat conditions such as autism, cerebral palsy, and traumatic brain injuries under the FDA's Expanded Access Program.

Cryo-Cell International, Inc. has 18 institutional owners and shareholders holding a total of 982,906 shares. Major institutional owners include Hamilton Lane Advisors Llc, SFI Advisors, LLC, Vanguard Group Inc, Massmutual Trust Co Fsb/adv, Geode Capital Management, Llc, Northern Trust Corp, Cerity Partners LLC, Citadel Advisors Llc, BlackRock, Inc., and Susquehanna International Group, Llp. Vanguard Group Inc. is the largest institutional shareholder, holding 150,990 shares, representing 1.87% of shares outstanding. In the last 24 months, institutional investors purchased 11,062 shares and sold 19,786 shares.